



# EHSF 2024

## Imagining Future Transitions



LYON | FEBRUARY 7–9, 2024

13<sup>th</sup> CONFERENCE OF THE EUROPEAN  
HIDRADENITIS SUPPURATIVA FOUNDATION



# TABLE OF CONTENTS

<b>01  </b>	<b>WELCOME MESSAGE</b>	
		03
<b>02  </b>	<b>GENERAL INFORMATION</b>	
		04
<b>03  </b>	<b>ABOUT EHSF</b>	
	Congresses	06
	Our history	06
	Last HSF, Inc. Board with European Participation	06
	Inauguration of EHSF e.V.	07
	Founding Members	07
<b>04  </b>	<b>COMMITTEES</b>	
	Organizing Committee	10
	Scientific Committee	11
	Health Care Providers	12
<b>05  </b>	<b>FEBRUARY 07, 2024 PROGRAM WED</b>	
	Overview	14
	Program	15
<b>06  </b>	<b>FEBRUARY 08, 2024 PROGRAM THU</b>	
	Overview	18
	Program	19
<b>07  </b>	<b>FEBRUARY 09, 2024 PROGRAM FRI</b>	
	Overview	24
	Program	25
<b>08  </b>	<b>CHAIRS</b>	
		29
<b>09  </b>	<b>POSTERS</b>	
		30
<b>10  </b>	<b>INDUSTRY PROGRAM</b>	
	Program	50
	Sponsors	52
<b>11  </b>	<b>IMPRINT</b>	
		59



## WELCOME MESSAGE

Here we are! All gathered for the 13th time for our Foundation's Conference. We thank the EHSF and its Board for entrusting us with the organization of this event, and all of you for being so many to attend.

We are happy and proud to welcome you to Lyon for a Conference that we have designed to be open and participatory.

The abstract submissions were not only numerous but also diverse and enriching. Registrations have been remarkable, bringing together delegates from all corners of the globe. This illustrates the perennial yet ever-evolving appeal of our annual event.

Our efforts have been dedicated to crafting a conference that combines a top-notch scientific program with the diverse aspects of the EHSF, covering both basic and clinical research, European and non-European contributions, as well as medical and surgical treatments.

Inclusivity has been a focal point, extending beyond the medical community to include nurses, acknowledged for their crucial role in patient care. We've also made efforts to involve those who may have indirect access to the scientific production of ESHF, ensuring patients feel integral to the conference through dedicated sessions like the Patient Organizations Meeting and Chat Room, Wish session, and Interactive session.

Moreover, we've broadened the perspective by incorporating artistic expression into the event. From the Opening Ceremony's concert to the SHARE Art Contest and live artistic performances on the final day, these events are open to everyone—patients and caregivers alike—emphasizing our collective dedication to a common goal.

Welcome to Lyon! Welcome to France! Welcome to the scholarly and amicable world of EHSF!



**Axel VILLANI, MD, PhD**  
Congress President  
Dept of Dermatology,  
Hôpital Edouard Herriot,  
Hospices Civils de Lyon



**Philippe GUILLEM, MD, PhD**  
Congress President  
Dept of Surgery,  
Clinique du Val d'Ouest,  
Ecully

# GENERAL INFORMATION

## LOCAL SCIENTIFIC & PROGRAM COMMITTEE

**Axel Villani (conference chair)**

**Philippe Guillem (conference chair)**

**Marie-Aleth Richard (LOC member)**

**Ziad Reguai (LOC member)**

**Denis Jullien (LOC member)**

## OVERALL LEARNING OBJECTIVES

To provide outstanding scientific and educational content focused on hidradenitis suppurativa.

To exchange ideas in the field of hidradenitis suppurativa and related topics, within an international scientific forum.

To address the theoretical and practical aspects of hidradenitis suppurativa.

## CME ACCREDITATION

**An application has been made to the UEMS EACCME® for CME accreditation of this event.**

## CERTIFICATES

**The certificate of attendance will be sent to you by e-mail/online download after the conference.**

## PRIZES & AWARDS

Best contribution prizes raised by EHSF e.V.

1st prize 1000 €

2nd prize 700 €

3rd prize 400 €

4th prize 200 €

5th prize 100 €

## Young investigators prizes raised by EHSF e.V.

3 prizes of 200 € for active participants under 30 year-old (lectures/poster presenters - who have to apply for the prize with CV, including date of birth and abstract submission).

## Prize for best Contribution from nurses

One prize of 200 € for active nurse participant (lectures/poster presenters).

## EHSF e.V. Scholarships for participants from countries in Africa

The EHSF e.V. announces 3 scholarships for participants from African countries, who want to actively contribute to its 13th Conference, 7-9.2.2024 in Lyon. The scholarship requirement is an active participation to the Conference with a scientific contribution. Residents of Dermatology and Venereology will be prioritised. Each scholarship in the amount of 1000 Euro will be reimbursed after the

Conference, following the presentation of relevant invoices for travel expenses and accommodation.

## REGISTRATION DESK OPENING HOURS

**Wednesday, February 7, 2024**

08:00–18:30

**Thursday, February 8, 2024**

07:30–18:30

**Friday, February 9, 2024**

07:30–16:00

## WELCOME RECEPTION

**Wednesday, February 7, 2024**

18:00–20:00

Exhibition area

## NETWORKING DINNER

**(access only for participants with a reservation)**

InterContinental Lyon - Hotel Dieu  
20 Quai Jules Courmont,  
69002 Lyon

**Thursday, February 8, 2024**

Doors open: 20:00

## MEET THE EXPERTS

**Friday, February 9, 18:00**

**(access only for participants with a reservation)**

Brasserie George  
30 Cr de Verdun Perrache  
69002 Lyon

## SHAe ART CONTEST

The Art Contest has been called for life with the aim to celebrate the power of creativity and explore the profound theme of HS. A unique perspective on the journey of patients, their struggles, treatments, and the profound impact of healthcare.

Live exhibition: Foyer in front of the Exhibition area

Digital access to all entries: dedicated E-poster stand in Forum 1

**Please don't forget to vote for your favourite artwork via the voting sheet received at the registration counter.**

## ART INSTALLATION BY REVVOL

You are invited to take an active part in the creation of an artwork by Alexandre Caillerec (<https://www.xelabottlepainting.com>)

**Place & Time:**

Exhibition area, Friday, February 9

## HS & SPORTS WORKSHOP BOOTH

You are invited to take an active part in 'HS and Sports' workshop throughout all conference days.

**Place:** Exhibition area

## LATEST PROGRAM

This book's content is as of 22.01.2024. For all updates please see the website.

► [www.ehsf2024.com](http://www.ehsf2024.com)



## ABOUT EHSF



### CONGRESSES

The 1<sup>st</sup> International Hidradenitis Suppurativa (HS) Research Symposium took place on 30.3–2.4.2006 in Dessau, Germany. The milestones of the Symposium were the so-called Dessauer definition of the disease and the HSF 2006 Outstanding Investigator Award presented to Prof. Gregor B.E. Jemec. The attendees of this legendary meeting were Dr. David R. Adams, USA; Dr. Andreas Altenburg, Germany; Ms. Michelle Barlow, USA; Dr. Martina Brunner, Germany; Dr. George Cotsarelis, USA; Dr. William Danby, USA; Dr. Alain Dupuy, France; Dr. Sabine Fimmel, Germany; Dr. Wolfgang Hartschuh, Germany; Dr. Dolores Herreros, Spain; Dr. Dorothee Hochheim, Germany; Mr. Robert Howes, USA; Dr. Peter Hull, Canada; Dr. Gregor Jemec, Denmark; Dr. Yvonne Kroening, Germany; Dr. Ichiro Kurokawa, Japan; Dr. Hjalmar Kurzen, Germany; Dr. Evgenia Makrantonaki, Germany; Dr. Anirban Mandal, UK; Dr. Lynette Margesson, USA; Dr. Wolfgang C. Marsch, Germany; Dr. W.H. Irwin McLean, Scotland; Dr. Samuel L. Moschella, USA; Dr. Ralf Paus, Germany; Dr. Uppala Radhakrishna, USA; Dr. Jean Revuz, France; Dr. Jihai Shi, Germany; Dr. Rodney Sinclair, Australia; Dr. John Sundberg, USA; Dr. Gilles Tachon, France; Dr. Antje Thielitz, Germany; Dr. Athanasios Theodoridis, Germany; Dr. Frangiski Tsatsou, Germany; Dr. Jan von der Werth, UK; and Dr. Christos C. Zouboulis, Germany. The 2nd International HS

Research Symposium took place on 5.3.2009 in San Francisco, IL, USA organized by Ms. Barlow and Profs. Paus and Zouboulis.

The 3<sup>rd</sup> and 4<sup>th</sup> International HS Research Symposia (first of the EHSF e.V.) took place on 27.–28.2.2014 and 19.–20.2.2015 in Brussels, Belgium.

The 5<sup>th</sup> International HS Conference, which was for the first time also open for non-members of the Society, took place on 10.–12.2.2016 in Berlin, Germany with 192 participants and 76 scientific contributions.

The 6<sup>th</sup> International HS Conference took place on 8.–10.2.2017 in Copenhagen, Denmark with 202 participants and 77 scientific contributions.

The 7<sup>th</sup> International HS Conference took place on 10.–12.2.2018 in Rotterdam, The Netherlands with more than 250 participants and 82 scientific contributions.

The 8<sup>th</sup> International HS Conference took place on 10.–12.2.2019 in Wroclaw, Poland with 406 participants and 119 scientific contributions.

The 9<sup>th</sup> International HS Conference took place on 5.–7.2.2020 in Athens, Greece. 422 participants from 48 countries with 137 scientific contributions participated at the conference.

The 10<sup>th</sup> and 11<sup>th</sup> International HS Conferences took place – due to the COVID-19 pandemic – at a digital mode – on 10.-12.2.2021 with 688 participants from 52 countries and 138 scientific contributions, and on 9.-11.2.2022 with 598 participants from 48 countries and 138 scientific contributions, respectively. 12% of the active 11th conference participants were young scientists under the age of 30 years.

The 12<sup>th</sup> International HS Conference was organized on 8.-10.2.2023 in Florence as a hybrid event. 757 participants from 45 countries (599 onsite) with 198 scientific contributions undersigned the continuous growth of the EHSF e.V. events. Again, 10% of the active participants were young scientists under the age of 30 years.

The 13<sup>th</sup> International HS Conference takes place 7.-9.2.2024 in Lyon as a presence only event and is planned to fulfil your scientific and networking expectations.

## OUR HISTORY

### Founding of HSF, Inc.

In 2005, Ms. Michele Barlow, a patient from San Diego, CA, USA, organized first funding to initiate the Hidradenitis Suppurativa Foundation, Inc. (HSF, Inc.), a tax-deducted organization according to the US law. In addition to Ms. Barlow as president and co-founder, Prof. Paus, director of basic research and co-founder, Prof. Zouboulis, director of clinical research and co-founder, Ms. Christine E. Pasela, San Diego, CA, USA, Ms. Sylvia

Shawcross, Chelsea, Quebec, Canada, Ms. Mary Veta, San Diego, CA, USA, and Ms. Lynn Edward Wedell, San Diego, CA, USA constituted the HSF Board. Experimental Dermatology became the official scientific journal of the HSF, Inc.

### LAST HSF, INC. BOARD WITH EUROPEAN PARTICIPATION

On 15.2.2012 a new HSF, Inc. board was elected with Prof. Zouboulis, President and responsible for hidradenitis suppurativa/acne inversa guidelines; Prof. Gregor B.E. Jemec, Copenhagen, Denmark, vice president and responsible for clinical research; Prof. Paus, vice president and responsible for experimental research, Ms. Barlow, treasurer and responsible for the Foundation; Prof. Richard Gallo, San Diego, CA, USA; Dr. Ichiro Kurokawa, Nishinomiya, Japan; Dr. George Varigos, Melbourne, Australia; Dr. Jan Lapins, Stockholm, Sweden; Dr. Paul Hazen, Westlake, OH, USA, responsible for patients' communication and for the HSF Inc. website, Thomas Winkler, Germany, president of the Deutsche Interessengemeinschaft Akne inversa e.V. as patients' representative; and Dr. Hessel H. van der See, Rotterdam, The Netherlands.

Despite the excellent and close cooperation among the involved scientists, the European Board members have recognized that bureaucratic issues in the USA made it more and more difficult for non-US citizens to run efficiently a US association. Therefore, Prof.

Zouboulis resigned as HSF, Inc. president and member of the board on 27.2.2013 followed by Prof. Paus, leaving the leadership of the HSF, Inc. to US colleagues with Dr. Paul Hazen as new HSF, Inc. president from 2.3.2013. During its first meeting on 24.3.2014 the new HSF, Inc. board has granted Ms. Barlow, Prof. Zouboulis and Prof. Paus the honorary Founders HSF, Inc. membership.

### **INAUGURATION OF EHSF E.V.**

The European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) has been inaugurated on 29.9.2012 in Prague, Czech Republic as independent, sister society of HSF, Inc. The EHSF e.V. has been registered and recognized as a non-profit, public benefit organization (gemeinnütziger e.V.) according to the German law. General assemblies, take place annually during the annual International Conference of the Society.

### **FOUNDING MEMBERS**

- Dr. Jurr Boer,  
Deventer/The Netherlands
- Prof. Dr. Veronique del Marmol,  
Brussels/Belgium
- Dr. Nemesha Desai,  
London/United Kingdom
- Dr. Deirdre Nathalie Dufour,  
Kalundborg/Denmark
- Dr. Lennart Emtestam,  
Stockholm/Sweden
- Prof. Dr. Gregor B.E. Jemec,  
Roskilde/Denmark
- Dr. Łukasz Matusiak,  
Wrocław/Poland
- Prof. Dr. Thrasivoulos Tzellos,  
Harstad, Troms/Norway
- Thomas Winkler,  
Lüdinghausen/Germany
- Dr. Hessel H. van der Zee,  
Rotterdam/The Netherlands
- Prof. Dr. Christos C. Zouboulis,  
Dessau-Rosslau/Germany

**SAVE THE DATE:**

---

**February 12–14, 2025**

**14<sup>th</sup> CONFERENCE OF THE EUROPEAN  
HIDRADENITIS SUPPURATIVA FOUNDATION**

**Vilnius, Lithuania**

**Conference chair:**

Ruta Ganceviciene

President of the Lithuanian Association  
of Dermatovenereology

# EHSF ORGANIZING COMMITTEE



**PHILIPPE GUILLEM**

(Ecully, France)



**GREGOR B.E. JEMEC**

(Roskilde, Denmark)



**VÉRONIQUE DEL MARMOL**

(Brussels, Belgium)



**ERROL P. PRENS**

(Rotterdam, The Netherlands)



**FRANCESCA PRIGNANO**

(Firenze, Italy)



**THRASYVOULOS TZELLOS**

(Bodø, Norway)



**AXEL VILLANI**

(Lyon, France)



**CHRISTOS C. ZOUBOULIS**

(Dessau, Germany)

# SCIENTIFIC COMMITTEE

Afsaneh Alavi  
Erkan Alpsoy  
Matthias Augustin  
Edileia Bagatin  
Falk Bechara  
Pierre-André Becherel  
Farida Benhadou  
Vincenzo Bettoli  
Yousef Binamer  
Jurr Boer  
Raffaele D. Caposiena Caro  
Nisha S. Chandran  
Arnon D. Cohen  
Véronique Del Marmol  
Maïa Delage-Toriel  
Antonella Di Cesare  
Alireza Firooz  
John W. Frew  
Ruta Ganceviciene  
Simone Garcovich  
Evangelos J. Giamarellos-Bourboulis  
Katalin Glasenhardt  
Matthias Goebeler  
Noah I. Goldfarb  
Philippe Guillem  
Wayne Gulliver  
Ariela Hafner  
Iltefat Hamzavi

Yuval Hilerowicz  
Barbara Hórvath  
Evgenia Hristakieva  
Robert E. Hunger  
John R. Ingram  
Dimitrios Ioannidis  
Gregor B.E. Jemec  
Olivier Join-Lambert  
Qiang Ju  
Alexander Katoulis  
Lajos Kemény  
Alexa B. Kimball  
Brian Kirby  
Joslyn S. Kirby  
Nathalie Kirsten  
Ishiro Kurokawa  
Hjalmar Kurzen  
Athanassios Kyrgidis  
Michelle Lowes  
Antonio Martorell  
Angelo V. Marzano  
Łukasz Matusiak  
Dillon Mintoff  
Alejandro Molina-Leyva  
Haley Naik  
Aude Nassif  
Georgios Nikolakis  
Hazel H. Oon  
José C. Pascual Ramirez  
Andreas Pinter  
Maurizio Podda  
Errol P. Prens

Dagmar Presser  
Francesca Prignano  
Luis Puig  
Tadas Raudonis  
Ziad Reguai  
Jorge Romani  
Marco Romanelli  
Elia Rosi  
Ditte M. Saunte  
Christopher J. Sayed  
Rodney Sinclair  
Dae H. Suh  
Andrea Szegedi  
Jacek C. Szepietowski  
Sylke Schneider-Burrus  
Terui Tadashi  
Linnea Thorlacius  
Ann-Marie Tobin  
Frangkiski Tsatsou  
Thrasyvoulos Tzellos  
Skaidra Valiukeviciene  
Hessel H. van der Zee  
Kelsey R. Van Straalen  
Axel Villani  
Esther von Stebut  
Eva Vilarrasa  
Seçil Vural  
Baoxi Wang  
Pierre Wolkenstein  
Ximena Wortsman  
Christos C. Zouboulis

# HEALTH CARE PROVIDERS

## OF THE EUROPEAN REFERENCE NETWORK OF RARE AND COMPLEX SKIN DISEASES (ERN SKIN)


The Department of Dermatology  
Hôpital Erasme  
Université Libre de Bruxelles, Bruxelles,  
Belgium

The Department of Dermatology, Zealand  
University Hospital  
University of Copenhagen, Roskilde,  
Denmark

The Departments of Dermatology,  
Venereology, Allergology and Immunology,  
Städtisches Klinikum Dessau, Brandenburg  
Medical School Theodor Fontane and  
Faculty of Health Sciences Brandenburg,  
Dessau, Germany



# SCIENTIFIC PROGRAM



# WEDNESDAY

# PROGRAM OVERVIEW

Wednesday, February 07, 2024 09:00–18:00		
Plenary	St. Clair	Forum 1
	09:00–10:30 Working groups/ projects	
		10:30–11:45 Poster Walk 1
11:15–12:45 GWAS		
12:45–13:15 Lunch		
13:15–14:45 CHISA		13:30–14:30 Poster Walk 2
	14:15–16:30 HS Nursing School	
15:00–16:30 European Guidelines		15:00–16:00 Poster Walk 3
16:30–17:00 Coffee		
17:00–17:15 Welcome and opening ceremony		
17:15–18:00 Invited lecture		
ALL DAY: HS & Sports workshop booth		

09:00–10:30

### Projects Meetings

HS in the ERN Skin: Syndromic HS, HS-related Autoinflammatory Syndromes

*Christos C. Zouboulis, Veronique del marmol, Angelo V. Marzano*

HS and Wound Healing:

*Marco Romanelli, Barbara Horvath*

Social Dermatology:

*Gregor Jemec*

HS and Antimicrobial Stewardship:

*Francesca Prignano*

Website Group & Social Media Group

*H. Hansen, K. Dakou, S. Darwiche-Hamie, T. Vileikis, S. Haselgruber*

Surgical Group:

*Philippe Guillem, Alejandro Molina-Leyva, Antonio Martorell*

Imaging in HS:

*Ximena Wortsman*

Evidence-based Decision Making and Outcomes:

*Thrasivoulos Tzello, John Ingram*

HS Basic Research:

*Axel Villani, Evangelos J. Giamarellos-Bourboulis*

10:30–11:45

### Poster Walk 1

Forum 1

Group 1 Chair: *Francesca Prignano*

Poster topic: Pathophysiology and Genetics: T1-P-01 to T1-P-09

Group 2 Chair: *Georgios Nikolakis*

Outcome Measures: T3-P-01 to T3-P-10

Group 3 Chair: *Philippe Guillem*

Poster topic: Burden and QoL: T4-P-01 to T4-P-10

Group 4 Chair: *Evangelos J. Giamarellos-Bourboulis*

Poster topic: Medical Treatments: T6-P-01 to T6-P-08

11:15–12:45

### EHSF/Regeneron GWAS study

St. Clair 3A

Coordinator: *Christos C. Zouboulis*

*Practical information on the initial steps and the logistics of the study program will be provided to the registered health care providers.*

<b>12:45–13:15</b>	<b>Lunch Break</b>	
<b>13:30–14:30</b>	<b>Poster Walk 2</b>	<b>Forum 1</b>
	Group 1 Chair: <i>Rolland Gyulai</i> Poster topic: Epidemiology: T2-P-01 to T2-P-07	
	Group 2 Chair: <i>Jacek C. Szepietowski</i> Poster topic: Comorbidities and Syndromic HS: T5-P-01 to T5-P-08	
	Group 3 Chair: <i>Axel Villani</i> Poster topic: Medical Treatments: T6-P-09 to T6-P-15	
<b>13:15–14:45</b>	<b>GHISA: Global Hidradenitis Suppurativa Atlas</b>	<b>Auditorium Lumière</b>
	Coordinator: <i>Gregor Jemec</i>	
13:15	GHISA – Future Perspectives <i>Gregor Jemec</i>	
13:30	HS in South-East Asia <i>Nisha Suyien Chandran</i>	
13:45	HS Epidemiology in Bangladesh <i>Mohammed Saiful Islam Bhuiyan</i>	
14:00	HS in South Africa <i>Haroon Saaed</i>	
14:15	HS in Chile <i>Francisco Reyes Baraona</i>	
14:30	HS in North Macedonia <i>Ivana Tuseva</i>	
<b>14:15–16:30</b>	<b>Nursing School</b>	<b>St. Clair 3A</b>
	Chairs: <i>Samantha Gaspard, Melody Grace, Stine Halgren Pedersen</i>	
14:15	Introduction	
14:20	Stigma <i>Barry McGrath, Christina Wilken</i>	
14:50	Women with HS <i>Shany Fisher</i>	
15:05	Nurse led clinics <i>Melody Grace</i>	
15:20	SEADS (smoking, exercise, alcohol, diet, sexuality) <i>Stine Halgren Pedersen, Shany Fisher</i>	

15:35	Wound dressings <i>Christelle Enault, Maria Solera Talamante</i>	
16:00	Discussion: What did the session teach us about HS nursing?	
16:20	Evaluation/Networking list	
<b>15:00–16:30</b>	<b>European Guidelines</b> Coordinator: <i>Christos C. Zouboulis</i> <i>Details on the publication procedure will be discussed among the authors.</i>	<b>Auditorium Lumière</b>
<b>15:00–16:00</b>	<b>Poster Walk 3</b>  Group 1 Chair: <i>Antonio Martorell-Calatayud</i> Poster topic: Medical Treatments: T6-P-16 to T6-P-23  Group 2 Chair: <i>Łukasz Matusiak</i> Poster topic: Surgical Treatments: T7-P-01 to T7-P-07  Group 3 Chair: <i>Sébastien Buche</i> Poster topic: Other: T9-P-01 to T9-P-08	<b>Forum 1</b>
<b>16:30–17:00</b>	<b>Coffee Break</b>	
<b>17:00–17:15</b>	<b>Welcome Address and Opening Ceremony</b>	<b>Auditorium Lumière</b>
<b>17:15–18:00</b>	<b>Invited Lecture</b>  Introduction <i>Axel Villani</i>  Getting into the DNA of HS <i>Errol P. Prens</i>	<b>Auditorium Lumière</b>



# THURSDAY

# PROGRAM OVERVIEW

Thursday, February 08, 2024 08:00-18:15	
Plenary	Forum 1
08:00-09:00 EHSF General Assembly	
09:00-10:30 ScS1- - Pathophysiology and Genetics	
10:30-11:00 Coffee	10:30-11:00 Poster Walk 4
11:00-12:30 ScS2- - Outcome Measures, Burden, QoL	
12:45-13:45 Lunch Industry Symposium	
14:00-15:00 Lunch Industry Symposium	
15:00-16:00 ScS3- - HS Around the World	
16:00-16:45 Coffee	16:00-16:45 Poster Walk 5
16:45-18:15 ScS4- - Medical Treatments 1	
ALL DAY: HS & Sports workshop booth	

08:00-09:00	<b>EHSF General Assembly</b>	<b>Auditorium Lumière</b>
09:00-10:30	<b>Scientific Session 1: Pathophysiology and Genetics</b> Chairs: <i>Axel Villani, Brian Kirby, Errol P. Prens</i>	<b>Auditorium Lumière</b>
09:00 T1-O-01	Characterization of the microbiome in biopsies of lesional and perilesional skin from patients with hidradenitis suppurativa and healthy controls <i>Jorge Romani</i>	
09:07 T1-O-02	Distinct fibroblast subsets contribute to inflammation and scarring in hidradenitis suppurativa (HS) <i>Conor Smith</i>	
09:14 T1-O-03	LAMA3: new gene associated with Hidradenitis Suppurativa susceptibility <i>Paola Maura Tricarico</i>	
09:21 T1-O-04	Contribution of MAIT cells in the development of Hidradenitis Suppurativa <i>Alexis Dumas</i>	
09:28 T1-O-05	Characterization of molecular endotypes in Hidradenitis Suppurativa <i>Ines Chricop</i>	
09:35 T1-O-06	Draining tunnel microbiome in hidradenitis suppurativa: modulation by time-course <i>Evangelos Giamarellos-Bourboulis</i>	
09:42 T1-O-07	Correlation between levels of IL-1 family members and clinical features of a population affected by Hidradenitis Suppurativa <i>Flavia Manzo Margiotta</i>	
09:49 T1-O-08	Modulation of blood proteome in hidradenitis suppurativa <i>Evangelos Giamarellos-Bourboulis</i>	
09:56 T1-O-09	Porphyromonas asaccharolytica crosses the skin barrier and activates immune responses in severe Hidradenitis Suppurativa <i>Viviane A. Agbogan</i>	
10:03 T1-O-10	DNA methylation-induced disruptions of drug transporters contribute to the development of drug resistance in Hidradenitis Suppurativa <i>Rakesh Rawal</i>	
10:10	Discussion	

10:30–11:00	<b>Poster Walk 4</b>  Group 1 Chair: <i>John R. Ingram</i> Poster topic: Pathophysiology and Genetics: T1-P-10 to T1-P-12  Group 2 Chair: <i>Farida Benhadou</i> Poster topic: Epidemiology: T2-P-08 to T2-P-11  Group 3 Chair: <i>Ruta Ganceviciene</i> Poster topic: Medical Treatments: T6-P-24 to T6-P-27	Forum 1
10:30–11:00	<b>Coffee Break</b>	
11:00–12:30	<b>Scientific Session 2: Outcome measures, burden, QoL</b> Chairs: <i>Alejandro Molina-Leyva, Thrasivoulos Tzellos, Joslyn S. Kirby</i>  <b>Outcome measures</b>  11:00 T3-O-06 Polygenic Score: a tool to facilitate the identification of Sporadic Hidradenitis Suppurativa Cases <i>Paola Maura Tricarico</i>  11:07 T3-O-07 Wound Area Severity Index (WASI): a novel tool for predicting healing times in hidradenitis suppurativa post-surgical wounds <i>Alessandra Michelucci</i>  11:14 T3-O-08 Evaluation of Hidradenitis Flare Thresholds for Patient- & Clinician-reported outcome measures <i>Joslyn Kirby</i>  11:21 T3-O-09 Major predictors of remission in hidradenitis suppurativa: an 8-year survival study with adalimumab <i>Eva Vilarrasa</i>  <b>Epidemiology</b>  11:28 T2-O-03 Identification of factors associated with severe hidradenitis suppurativa, using Hurley staging and Metascore <i>Mathieu Daoud</i>  <b>Burden and QoL</b>  11:35 T4-O-01 Psoriasis associated with hidradenitis suppurativa: a large-scale worldwide study <i>Bruno Halioua</i>  11:42 T4-O-02 Severe sexual impairment in patients with hidradenitis suppurativa <i>Piotr Krajewski</i>	Auditorium Lumière

11:49 T4-O-03	The impact of pain on mental health in patients with hidradenitis suppurativa: Results from the HS Uncovered global patient survey <i>Georgios Kokolakis</i>	
11:56 T4-O-04	Association between skin-related quality of life and race in patients with hidradenitis suppurativa <i>Amit Garg</i>	
12:03 T4-O-05	Prevalence of feelings of stigma and coping strategies among patients with Hidradenitis suppurativa in France <i>Bruno Halioua</i>	
12:10	Discussion	
12:45-13:45	<b>Lunch Industry Symposium</b> For details see page 50	Auditorium Lumière
14:00-15:00	<b>Lunch Industry Symposium</b> For details see page 50	Auditorium Lumière
15:00-16:00	<b>Scientific Session 3: HS Around the World</b> Chairs: <i>Marie-Aleth Richard, John R. Ingram, Ditte M. Saunte</i>	Auditorium Lumière
15:00 T3-O-02	Racial and ethnic disparities of clinical characteristics and symptoms among patients with hidradenitis suppurativa: a worldwide study <i>Bruno Halioua</i>	
15:07 T2-O-01	Assessment of Clinician Knowledge on Hidradenitis Suppurativa: Insights from a Multidisciplinary Survey Study <i>Klaudia Knecht-Gurwin</i>	
15:14 T3-O-01	e-Health literacy in adults with hidradenitis suppurativa (HS): a worldwide study in 20 countries to explore associated factors <i>Bruno Halioua</i>	
15:23 T2-O-02	Hidradenitis suppurativa tarda: defining an understudied elderly population <i>Nicole Koerts</i>	
15:30 T9-O-01	New perspectives on Mammary Hidradenitis Suppurativa <i>Ariany Denofre</i>	

- 15:37 **T1-O-10** DNA Dysregulation is Linked to Persistent Pain in Hidradenitis Suppurativa  
*Uppala Radhakrishna*
- 15:44 Discussion

- 16:00–16:45 Poster Walk 5 Forum 1**
- Group 1 Chair: *Hessel H. van der Zee*  
Poster topic: Comorbidities and Syndromic HS: T5-P-09 to T5-P-14
- Group 2 Chair: *Antonio Martorell*  
Poster topic: Medical Treatments: T6-P-28 to T6-P-32
- Group 3 Chair: *François Aubin*  
Poster Topic: Other: T9-P-09 to T9-P-14

**16:00–16:45 Coffee Break**

- 16:45–18:15 Scientific Session 4: Medical Treatments 1 Auditorium Lumière**  
Chairs: *Angelo Marzano, Christos C. Zouboulis, Evangelos J. Giamarellos-Bourboulis*
- 16:45 **T3-O-04** Efficacy of Secukinumab Assessed Using International Hidradenitis Suppurativa Severity Scoring System (IH54) in Patients with Hidradenitis Suppurativa: Post Hoc Analysis of Week 52 Data from the SUNSHINE and SUNRISE Trials  
*Christos C. Zouboulis*
- 16:52 **T6-O-02** Anti-citrullinated histone antibody CIT-013: Targeting neutrophil extracellular traps as an anti-inflammatory therapy in hidradenitis suppurativa  
*Stephanie van Dalen*
- 16:59 **T6-O-05** Depth of the Efficacy Response to Upadacitinib Treatment in Moderate-to-Severe Hidradenitis Suppurativa (HS)  
*Thrasylvoulos Tzellos*
- 17:06 **T6-O-20** Insight into the window of opportunity: Low therapeutic burden is associated with better effectiveness of secukinumab in patients with moderate-to-severe hidradenitis suppurativa  
*Sofia Haselgruber*

- 17:13 T6-O-12 Bimekizumab Efficacy by Disease Duration in Patients with Moderate to Severe Hidradenitis Suppurativa: Week 48 Results from BE HEARD I & II  
*Alexa Kimball*
- 17:20 T6-O-14 ADOLESBIOHS: A real-world multicentre retrospective study on the effectiveness, safety, and dosage of Adalimumab in adolescents with hidradenitis suppurativa.  
*Mercè Grau-Pérez*
- 17:27 T6-O-15 Patient and Physician Preferences for Attributes Associated with Biologic Treatments for Hidradenitis Suppurativa  
*John Ingram*
- 17:34 T6-O-18 Exploratory Trial of Topical Ruxolitinib for Early Stage Hidradenitis Suppurativa  
*Joslyn Kirby*
- 17:41 T6-O-19 The inflammatory pattern of Hidradenitis suppurativa patients after treatment with antibiotics  
*Anke Koenig*
- 17:48 T7-O-04 Secukinumab treatment interruptions and post-operative safety profile in patients with moderate to severe hidradenitis suppurativa undergoing surgery: a post-hoc analysis from the SUNSHINE and SUNRISE trials  
*Falk Bechara*
- 17:55 Discussion



# FRIDAY

# PROGRAM OVERVIEW

Friday, February 09, 2024 08:00–17:45		
Main Room	St. Clair 3AB	Forum 1
08:00–10:00 Live Surgery Session		
10:00–10:30 Coffee		10:00–10:30 Poster Walk 6
10:30–12:30 Sc55- - Medical Treatments 2	10:30–12:30 Patient Organisations` Meeting & Chat Room	
12:45–13:45 Lunch Industry Symposium		
14:00–15:30 Sc56- - Comorbidities	14:00–15:00 “WISH” Session	
15:30–16:30 Sc57- - Interactive Session		
16:30–17:15 Coffee		
17:15–17:45 Awards and Closure Address		
HS & Sports workshop booth, Art Installation		

08:00-10:00	<b>Live Surgery Session – broadcast from Clinique du Val d'Ouest (Philippe Guillem)</b> Moderator: <i>Falk Bechara, Stephanie Goldberg, Hessel H. van der Zee, Anne-Cécile Ezanno</i>	Auditorium Lumière
T3-O-03	Integrated Clinical and Ultrasound score: The Revolutionary Role of Ultra-High Frequency Ultrasound <i>Valentina Dini</i>	
T7-O-02	Clinical Precision in Hidradenitis Suppurativa Lesion Excision: A Prospective Study of 110 Cases Utilizing Ultrasound-Guided Surgical Techniques <i>Antonio Martorell</i>	
T7-O-01	Optimizing outcomes in hidradenitis suppurativa surgical treatment: a comprehensive analysis of postoperative complications and quality of life impact <i>Alessandra Michelucci</i>	
T7-O-03	Deroofing in Hidradenitis Suppurativa: one-year experience in two Chilean health centers. <i>Francisco Reyes-Baraona</i>	
10:00-10:30	<b>Coffee Break</b>	
10:00-10:30	<b>Poster Walk 6</b> Group 1 Chair: <i>Maïa Delage-Toriel</i> Poster topic: T6-P-33 to T6-P-36 Group 2 Chair: <i>Marco Romanelli</i> Poster topic: Nursing and Supportive Care T8-P-01 to T8-P-02	
10:30-12:30	<b>Patient Organisations' Meeting &amp; Chat Room</b> Coordination: <i>Barry McGrath, Bente Villumsen, Brindley Brooks</i>	St. Clair 3A
10:30-12:30	<b>Scientific Session 5: Medical Treatments 2</b> Chairs: <i>Pierre-André Becherel, Dillon Mintooff, Ziad Reguiai</i>	Auditorium Lumière
10:30 T3-O-05	Bimekizumab Impact on Lesion Count by Anatomical Region in Moderate to Severe Hidradenitis Suppurativa: Results to Week 48 from BE HEARD I & II <i>Hessel van der Zee</i>	

- 10:37 T6-O-03 Maintenance of Response to Povorcitinib in Patients With Hidradenitis Suppurativa: Efficacy During the Open-Label Extension Period of a Phase 2 Study  
*Falk Bechara*
- 10:44 T6-O-04 The IL-17A- and IL-17F-inhibiting Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 12 International Hidradenitis Suppurativa Severity Score System (IHS4) results from the Phase 2 MIRA trial  
*Brian Kirby*
- 10:51 T6-O-06 Bimekizumab Impact on Dichotomous IHS4 Response Levels in Patients with Moderate to Severe Hidradenitis Suppurativa: Results up to Week 48 from BE HEARD I & II  
*Thrasylvoulos Tzellos*
- 10:58 T6-O-07 Biotechnology from Germany: HS 3D-SeboSkin model enables the preclinical exploration of therapeutic candidates for hidradenitis suppurativa / acne inversa  
*Christos C. Zouboulis*
- 11:05 T6-O-08 Molecular signature highlights the therapeutic significance of bimekizumab in cephalic/facial hidradenitis suppurativa  
*Marine Chastagner*
- 11:12 T6-O-10 Long-term, real-world effectiveness of adalimumab in the treatment of hidradenitis suppurativa  
*Georgia Vradeli*
- 11:16 T6-O-11 Bimekizumab demonstrates effective responses and safety in hidradenitis suppurativa: short-term real-world observational multicentric study from Spain  
*Miguel Mansilla-Polo*
- 11:26 T6-O-13 Real-World Evidence of Secukinumab in Hidradenitis Suppurativa: Insights from a multicenter retrospective analysis of 263 cases  
*Antonio Martorell*
- 11:33 T6-O-16 Brodalumab drug survival in patients with HS – a single-centre's experience  
*Emily Pender*

11:40 T6-O-17	LAight therapy is an effective and gentle treatment for hidradenitis suppurativa in adolescence- Results from 96 patients <i>Simone Garcovich</i>	
11:47 T6-O-09	Secukinumab in severe hidradenitis suppurativa (HS): 2-week interval (Q2) seems better than 4-week (Q4) in a real life study <i>Pierre-Andre Becherel</i>	
11:54 T3-O-10	Patient-reported outcomes categorised by achievement of dichotomous clinical outcomes in the SUNRISE and SUNSHINE Phase 3 trials for hidradenitis suppurativa: A post hoc analysis <i>John Ingram</i>	
12:03	Discussion	
12:45-13:45	<b>Industry Symposium</b> For details see page 50	Auditorium Lumière
14:00-15:00	<b>“WISH” Session</b> Chair: PANASH ( <i>Paramedics And Nurses Against Suppurative Hidradenitis</i> )	St. Clair 3
14:00-15:30	<b>Scientific Session 6: Comorbidity</b> Chairs: <i>Gregor Jemec, Véronique del Marmol, Francesca Prignano</i>	Auditorium Lumière
14:00 T5-O-01	Hidradenitis suppurativa in patients with Dowling-Degos disease: a case series and literature review with a focus on disease phenotype <i>Juan Garcias-Ladaria</i>	
14:07 T5-O-02	Incidence of non-infectious uveitis among patients with hidradenitis suppurativa <i>Temitope Ayodele</i>	
14:14 T5-O-03	Increased coronary atherosclerotic plaque in hidradenitis suppurativa compared to age- and sex-matched controls: <i>Niamh Kearney</i>	

- 14:21 T5-O-04 Diagnosing occult inflammatory bowel disease in patients with hidradenitis suppurativa using sign/symptom-based questionnaires and faecal calprotectin testing  
*Niamh Kearney*
- 14:28 T5-O-05 Fecal calprotectin test for hidradenitis suppurativa patients with chronic inflammatory intestinal disorders  
*Krisztian Gaspar*
- 14:35 T5-O-06 Incidence of Nonalcoholic Fatty Liver Disease among Patients with Hidradenitis Suppurativa  
*Amit Garg*
- 14:42 T5-O-07 Comorbidities and risk factors associated with hidradenitis suppurativa: A systematic review and meta-analysis  
*Naila Bouadi*
- 14:49 T5-O-08 Lymphedema in hidradenitis suppurativa: a multicenter case series  
*Patricia Garbayo-Salmons*
- 14:56 T5-O-09 Hidradenitis suppurativa patients are at higher risk of developing life-threatening cardiovascular disorders: a large-scale, propensity-matched global retrospective cohort study.  
*Piotr Krajewski*
- 15:03 T6-O-01 Semaglutide for weight loss in obese patients with hidradenitis suppurativa and its impact on disease control and quality of life  
*Emily Pender*
- 15:10 Discussion

**15:30-16:30 Scientific Session 7: Interactive Session**  
Chairs: *Farida Benhadou, Philippe Guillem, Marine Chastagner*

**Auditorium  
Lumière**

**16:30-17:15 Coffee Break**

**17:15-17:45 Awards and Closure Address**

**Auditorium  
Lumière**



# CHAIRS

<b>François Aubin</b> , France	<b>Dillon Mintoff</b> , Malta
<b>Falk Bechara</b> , Germany	<b>Alejandro Molina-Leyva</b> , Spain
<b>Pierre-André Becherel</b> , France	<b>Georgios Nikolakis</b> , Germany
<b>Farida Benhadou</b> , Belgium	<b>Errol P. Prens</b> , The Netherlands
<b>Sebastien Buche</b> , France	<b>Francesca Prignano</b> , Italy
<b>Brindley Brooks</b> , USA	<b>Ziad Reguiat</b> , France
<b>Marine Chastagner</b> , France	<b>Marie-Aleth Richard</b> , France
<b>Véronique Del Marmol</b> , Belgium	<b>Marco Romanelli</b> , Italy
<b>Maïa Delage-Toriel</b> , France	<b>Ditte M. Saunte</b> , Denmark
<b>Anne-Cecile Ezanno</b> , France	<b>Jacek C. Szebietowski</b> , Poland
<b>Ruta Ganceviciene</b> , Lithuania	<b>Thrasyvoulos Tzellos</b> , Norway
<b>Samantha Gaspard</b> , France	<b>Hessel H. van der Zee</b> , The Netherlands
<b>Evangelos J. Giamarellos-Bourboulis</b> , Greece	<b>Axel Villani</b> , France
<b>Stephanie Goldberg</b> , USA	<b>Bente Villumsen</b> , Denmark
<b>Melody Grace</b> , Singapore	<b>Ximena Wortsman</b> , Chile
<b>Philippe Guillem</b> , France	<b>Christos C. Zouboulis</b> , Germany
<b>Roland Gyulai</b> , Hungary	
<b>Stine Halgren Pedersen</b> , Denmark	
<b>Barbara Hórvath</b> , The Netherlands	
<b>John R. Ingram</b> , United Kingdom	
<b>Gregor B.E. Jemec</b> , Denmark	
<b>Brian Kirby</b> , Ireland	
<b>Joslyn Kirby</b> , USA	
<b>Łukasz Matusiak</b> , Poland	
<b>Angelo Valerio Marzano</b> , Italy	
<b>Antonio Martorell</b> , Spain	
<b>Barry McGrath</b> , Ireland	

# POSTERS



## T1 Pathophysiology and Genetics

- T1-O-01** Characterization of the microbiome in biopsies of lesional and perilesional skin from patients with hidradenitis suppurativa and healthy controls  
*Jorge Romani*
- T1-O-02** Distinct fibroblast subsets contribute to inflammation and scarring in hidradenitis suppurativa (HS)  
*Conor Smith*
- T1-O-03** LAMA3: new gene associated with Hidradenitis Suppurativa susceptibility  
*Paola Maura Tricarico*
- T1-O-04** Contribution of MAIT cells in the development of Hidradenitis Suppurativa  
*Alexis Dumas*
- T1-O-05** Characterization of molecular endotypes in Hidradenitis Suppurativa  
*Ines Chricap*
- T1-O-06** Draining tunnel microbiome in hidradenitis suppurativa: modulation by time-course  
*Evangelos Giamarellos-Bourboulis*
- T1-O-07** Correlation between levels of IL-1 family members and clinical features of a population affected by Hidradenitis Suppurativa  
*Flavia Manzo Margiotta*
- T1-O-08** Modulation of blood proteome in hidradenitis suppurativa  
*Evangelos Giamarellos-Bourboulis*
- T1-O-09** *Porphyromonas asaccharolytica* crosses the skin barrier and activates immune responses in severe Hidradenitis Suppurativa  
*Viviane A Agbogan*

**T1-O-10** DNA methylation-induced disruptions of drug transporters contribute to the development of drug resistance in Hidradenitis Suppurativa

*Rakesh Rawal*

**T1-O-11** DNA Dysregulation is Linked to Persistent Pain in Hidradenitis Suppurativa

*Uppala Radhakrishna*

**Poster Walk 1 – Group 1**

**T1-P-01** Quantitative Trait Loci Mapping in Hidradenitis Suppurativa

*Theodora Kanni*

**T1-P-02** In-depth characterization of the inflammatory mechanisms underlying hidradenitis suppurativa (HS): Comparison of perilesional skin with inflammatory nodules and tunnels

*Eva Cullen*

**T1-P-03** Evidence of a role for IL-17F in the pathophysiology of dermal tunnels in hidradenitis suppurativa: Implications for therapeutic interventions

*Kristian Reich*

**T1-P-04** Study of the transcriptomic profile in skin of patients with Hidradenitis suppurativa. HidraSMEx Study.

*Jorge Romani*

**T1-P-05** Plasma calprotectin as an index of draining tunnel formation in hidradenitis suppurativa

*Theodora Kanni*

**T1-P-06** The effect of adalimumab treatment on the vascularization of hidradenitis suppurativa lesions: a pilot study

*Dubravka Vuković*

**T1-P-07** Exploratory study to evaluate changes in inflammatory pattern in patients with active moderate-to-severe hidradenitis suppurativa

*Tanja Ickelsheimer*

**T1-P-08** Inflammatory pattern is changed 6 weeks after adalimumab initiation in hidradenitis suppurativa

*Anke Koenig*

**T1-P-09** Ultra High Frequency Ultrasound-guided biopsy and tissue biomarkers in Hidradenitis Suppurativa patients

*Flavia Manzo Margiotta*

**Poster Walk 4 – Group 1**

**T1-P-10** Integrating Artificial Intelligence for Morphological Analysis and Drug Screening in Hidradenitis Suppurativa Skin Organoids

*Cecile Nait Meddour*

- T1-P-11** Inborn Errors of Immunity help to resolve the immunological landscape of Hidradenitis Suppurativa.  
*Lynn Petukhova*
- T1-P-12** An ancestrally diverse HS meta-analysis of nine hidradenitis suppurativa cohorts identifies four risk loci.  
*Lynn Petukhova*

## **T2 Epidemiology**

- T2-O-01** Assessment of Clinician Knowledge on Hidradenitis Suppurativa: Insights from a Multidisciplinary Survey Study  
*Klaudia Knecht-Gurwin*
- T2-O-02** Hidradenitis suppurativa tarda: defining an understudied elderly population  
*Nicole Koerts*
- T2-O-03** Identification of factors associated with severe hidradenitis suppurativa, using Hurley staging and Metascore  
*Mathieu Daoud*
- Poster Walk 2 – Group 1**
- T2-P-01** Belgian patients of the European Registry for Hidradenitis Suppurativa (ERHS-Be): data, scores and phenotypes since 2015  
*Stephanie Heudens*
- T2-P-02** Demographic Features of Hidradenitis Suppurativa: A Single-center Retrospective analysis of 357 patients in Northern Greece.  
*Sofia-Andriani Theodorelou-Charitou*
- T2-P-03** Hidradenitis suppurativa (HS) in diabetes mellitus patients: A link between alterations in smoking intensity and the risk of developing HS  
*Hwa Jung Yook*
- T2-P-04** Presentation of the medical history of 210 HS patients from the official Registry of “Andreas Sygros” Hospital for Venereal and Cutaneous Diseases  
*Aikaterini Liakou*
- T2-P-05** Delay in hidradenitis suppurativa diagnosis: Are we getting better? A retrospective registry-based study  
*Ourlana Efthymiou*
- T2-P-06** Clinical and epidemiological characteristics of outpatients with hidradenitis suppurativa in a Brazilian hospital  
*Magda Weber*
- T2-P-07** The influence of smoking and obesity on hidradenitis suppurativa: a population-based retrospective analysis in South Korea  
*Jihae Lee*

**Poster Walk 4 – Group 2**

- T2-P-08** Lifestyle in Hidradenitis Suppurativa  
*Silke Bouwman*
- T2-P-09** Cigarette smoking preceding onset of hidradenitis suppurativa symptoms in patients attending a hidradenitis suppurativa specialist clinic.  
*Emily Pender*
- T2-P-10** Prevalence of Hidradenitis Suppurativa in Belgium: Validation of a screening questionnaire  
*Fadwa El Aissoug*
- T2-P-11** The Copenhagen Hidradenitis Suppurativa Cohort: results from the first 700 patients  
*Nikolaj Holgersen*

**T3 Outcome Measures**

- T3-O-01** e-Health literacy in adults with hidradenitis suppurativa (HS): a worldwide study in 20 countries to explore associated factors  
*Bruno Halioua*
- T3-O-02** Racial and ethnic disparities of clinical characteristics and symptoms among patients with hidradenitis suppurativa: a worldwide study  
*Bruno Halioua*
- T3-O-03** Integrated Clinical and Ultrasound score: The Revolutionary Role of Ultra-High Frequency Ultrasound  
*Valentina Dini*
- T3-O-04** Efficacy of Secukinumab Assessed Using International Hidradenitis Suppurativa Severity Scoring System (IHS4) in Patients with Hidradenitis Suppurativa: Post Hoc Analysis of Week 52 Data From the SUNSHINE and SUNRISE Trials  
*Christos C. Zouboulis*
- T3-O-05** Bimekizumab Impact on Lesion Count by Anatomical Region in Moderate to Severe Hidradenitis Suppurativa: Results to Week 48 from BE HEARD I & II  
*Hessel van der Zee*
- T3-O-06** Polygenic Score: a tool to facilitate the identification of Sporadic Hidradenitis Suppurativa Cases  
*Paola Maura Tricarico*
- T3-O-07** Wound Area Severity Index (WASI): a novel tool for predicting healing times in hidradenitis suppurativa post-surgical wounds  
*Alessandra Michelucci*
- T3-O-08** Evaluation of Hidradenitis Flare Thresholds for Patient- & Clinician-reported outcome measures  
*Joslyn Kirby*

- T3-O-09** Major predictors of remission in hidradenitis suppurativa: an 8-year survival study with adalimumab  
*Eva Vilarrasa*
- T3-O-10** Patient-reported outcomes categorised by achievement of dichotomous clinical outcomes in the SUNRISE and SUNSHINE Phase 3 trials for hidradenitis suppurativa: A post hoc analysis  
*John Ingram*
- Poster Walk 1 – Group 2**
- T3-P-01** Viewpoint on the evaluation of severity and treatment effects in mild hidradenitis suppurativa: the cumulative IHS4 (IHS4-C)  
*Johanna van Huijstee*
- T3-P-02** Patient-reported outcomes from the global, randomized, double-blind, placebo-controlled Phase 2 MIRA trial of the IL-17A- and IL-17F-inhibiting Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS)  
*John Ingram*
- T3-P-03** Patterns of surgical procedures and medical treatments among patients with hidradenitis suppurativa before and after referral to specialized dermatological hospital care  
*Nana Aviaaja Roseno*
- T3-P-04** The duel: Dermatologists vs. ChatGPT in Hidradenitis Suppurativa  
*Sofia Haselgruber*
- T3-P-05** Development and External Validation of the Hidradenitis Suppurativa Cutaneous Abscess Prediction Score-2 (HSCAPS-2): A Clinical Decision Support Tool for Diagnosis of Hidradenitis Suppurativa over Cutaneous Abscess  
*Amit Garg*
- T3-P-06** Innovative Application of “Vectra” Imaging in Assessing Hidradenitis Suppurativa lesions: Preliminary Findings and Future Prospects  
*Aikaterini Liakou*
- T3-P-07** IHS4 Outcomes with Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Results from the BE HEARD I & II Phase 3 Trials  
*Christos Zouboulis*
- T3-P-09** Intra-rater agreement of lesion counts in hidradenitis suppurativa  
*Amit Garg*
- T3-P-10** What If in Suppurative Hidradenitis: results of a “If you have a magic wand ...” survey among patients with hidradenitis suppurativa  
*Barry McGrath*

#### T4 Burden and QoL

- T4-O-01** Psoriasis associated with hidradenitis suppurativa: a large-scale worldwide study  
*Bruno Halioua*

- T4-O-02** Severe sexual impairment in patients with hidradenitis suppurativa  
*Piotr Krajewski*
- T4-O-03** The impact of pain on mental health in patients with hidradenitis suppurativa: Results from the HS Uncovered global patient survey  
*Georgios Kokolakis*
- T4-O-04** Association between skin-related quality of life and race in patients with hidradenitis suppurativa  
*Amit Garg*
- T4-O-05** Prevalence of feelings of stigma and coping strategies among patients with Hidradenitis suppurativa in France  
*Bruno Halioua*
- Poster Walk 1 – Group 3**
- T4-P-01** Characterising baseline assessments from an implementation science study to improve the diagnosis and management of patients with hidradenitis suppurativa  
*Pierre André Becherel*
- T4-P-02** Concordance between self-reported weight and measured weight: a case-control study in patients with Hidradenitis Suppurativa.  
*Pedro Navarro-Guillamon*
- T4-P-03** Self-management-competency as a new target in Hidradenitis suppurativa care  
*Uwe Kirschner*
- T4-P-04** Incidence of anxiety disorders in adults and children with hidradenitis suppurativa  
*Amit Garg*
- T4-P-05** Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa: A Focus on Patient Quality of Life and Depth of Responses from BE HEARD I & II to Week 48  
*Joslyn Kirby*
- T4-P-06** Racial and ethnic disparities of burden and feelings of stigmatisation among patients with hidradenitis suppurativa : a worldwide study  
*Bruno Halioua*
- T4-P-07** Prevalence and risk factors for selfie phobia in people with hidradenitis suppurativa: a worldwide study in 20 countries  
*Bruno Halioua*
- T4-P-08** Types of insomnia in patients suffering from Hidradenitis suppurativa  
*Bruno Halioua*
- T4-P-09** Hurley Stage 3 Hidradenitis Suppurativa in pregnancy: An area of unmet need  
*Elizabeth Keeling*
- T4-P-10** Diagnostic delays in hidradenitis suppurativa: Have we made improvements?  
*Gregg Murray*

**T5 Comorbidities and Syndromic HS**

- T5-O-01** Hidradenitis suppurativa in patients with Dowling-Degos disease: a case series and literature review with a focus on disease phenotype  
*Juan Garcias-Ladaria*
- T5-O-02** Incidence of non-infectious uveitis among patients with hidradenitis suppurativa  
*Temitope Ayodele*
- T5-O-03** Increased coronary atherosclerotic plaque in hidradenitis suppurativa compared to age- and sex-matched controls  
*Niamh Kearney*
- T5-O-04** Diagnosing occult inflammatory bowel disease in patients with hidradenitis suppurativa using sign/symptom-based questionnaires and faecal calprotectin testing  
*Niamh Kearney*
- T5-O-05** Fecal calprotectin test for hidradenitis suppurativa patients with chronic inflammatory intestinal disorders  
*Krisztian Gaspar*
- T5-O-06** Incidence of Nonalcoholic Fatty Liver Disease among Patients with Hidradenitis Suppurativa  
*Amit Garg*
- T5-O-07** Comorbidities and risk factors associated with hidradenitis suppurativa: A systematic review and meta-analysis  
*Naila Bouadi*
- T5-O-08** Lymphedema in hidradenitis suppurativa: a multicenter case series  
*Patricia Garbayo-Salmons*
- T5-O-09** Hidradenitis suppurativa patients are at higher risk of developing life-threatening cardiovascular disorders: a large-scale, propensity-matched global retrospective cohort study.  
*Piotr Krajewski*

**Poster Walk 2 – Group 2**

- T5-P-01** Dissecting Cellulitis of the Scalp: Severe Presentation Requiring multidisciplinary attention.  
*Veronica Mora-Fernandez*
- T5-P-02** Syndromic hidradenitis suppurativa in the Belgian European Registry for Hidradenitis Suppurativa (ERHS-Be)  
*Anne-Sophie Sarkis*
- T5-P-03** Scalp Involvement in Hidradenitis Suppurativa: A Cross-Sectional Pilot Study. SCALPHS Project  
*Pablo Fernández-Crehuet Serrano*

- T5-P-04** Cutaneous Crohn's disease in patients with hidradenitis suppurativa, do we know how to recognize it?  
*Ines Gracia-Darder*
- T5-P-05** Depression severity in adults with hidradenitis suppurativa  
*Konstantinos Leventogiannis*
- T5-P-06** Modulation of cytokine production in patients with hidradenitis suppurativa by COVID medical history.  
*Konstantinos Leventogiannis*
- T5-P-07** The differentiation between acne vulgaris in hs and acne-like hs: expanded case study and new classification  
*Vincenzo Bettoli*
- T5-P-08** Hidradenitis suppurativa and ocular diseases: Real-World evidence of about 130,000 patients.  
*Jennifer von Stebut*

**Poster Walk 5 – Group 1**

- T5-P-09** Management of hidradenitis suppurativa in HIV patients. Series of seven cases.  
*Mar Luque-Luna*
- T5-P-10** PASH Syndrome: Clinical and Ultrasonographic findings  
*Gavril Poterov*
- T5-P-11** Syndromic familial autoinflammatory hidradenitis suppurativa: report of three cases  
*Radostina Deliyska*
- T5-P-12** Proposal for expansion of hidradenitis suppurativa phenotype classification.  
*Anna Pirogova*
- T5-P-13** Risk of cutaneous squamous cell carcinoma in patients with hidradenitis suppurativa treated with anti-TNF-alpha – results from a 12-year multicentric observational prospective study  
*Monika Arenbergerova*
- T5-P-14** Differences between men and women: how hidradenitis suppurativa affects each gender?  
*Stephanie Heudens*

**T6 Medical Treatments**

- T6-O-01** Semaglutide for weight loss in obese patients with hidradenitis suppurativa and its impact on disease control and quality of life  
*Emily Pender*
- T6-O-02** Anti-citrullinated histone antibody CIT-013: Targeting neutrophil extracellular traps as an anti-inflammatory therapy in hidradenitis suppurativa  
*Stephanie van Dalen*

- T6-O-03** Maintenance of Response to Povorcitinib in Patients With Hidradenitis Suppurativa: Efficacy During the Open-Label Extension Period of a Phase 2 Study  
*Falk Bechara*
- T6-O-04** The IL-17A- and IL-17F-inhibiting Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 12 International Hidradenitis Suppurativa Severity Score System (IHS4) results from the Phase 2 MIRA trial  
*Brian Kirby*
- T6-O-05** Depth of the Efficacy Response to Upadacitinib Treatment in Moderate-to-Severe Hidradenitis Suppurativa (HS)  
*Thrasyvoulos Tzellos*
- T6-O-06** Bimekizumab Impact on Dichotomous IHS4 Response Levels in Patients with Moderate to Severe Hidradenitis Suppurativa: Results up to Week 48 from BE HEARD I & II  
*Thrasyvoulos Tzellos*
- T6-O-07** Biotechnology from Germany: HS 3D-SeboSkin model enables the preclinical exploration of therapeutic candidates for hidradenitis suppurativa / acne inversa  
*Christos C. Zouboulis*
- T6-O-08** Molecular signature highlights the therapeutic significance of bimekizumab in cephalic/facial hidradenitis suppurativa  
*Marine Chastagner*
- T6-O-09** Secukinumab in severe hidradenitis suppurativa (HS): 2-week interval (Q2) seems better than 4-week (Q4) in a real life study  
*Pierre-Andre Becherel*
- T6-O-10** Long-term, real-world effectiveness of adalimumab in the treatment of hidradenitis suppurativa  
*Georgia Vradeli*
- T6-O-11** Bimekizumab demonstrates effective responses and safety in hidradenitis suppurativa: short-term real-world observational multicentric study from Spain  
*Miguel Mansilla-Polo*
- T6-O-12** Bimekizumab Efficacy by Disease Duration in Patients with Moderate to Severe Hidradenitis Suppurativa: Week 48 Results from BE HEARD I & II  
*Alexa Kimball*
- T6-O-13** Real-World Evidence of Secukinumab in Hidradenitis Suppurativa: Insights from a multicenter retrospective analysis of 263 cases  
*Antonio Martorell*
- T6-O-14** ADOLESBIOHS: A real-world multicentre retrospective study on the effectiveness, safety, and dosage of Adalimumab in adolescents with hidradenitis suppurativa.  
*Mercè Grau-Pérez*

- T6-O-15** Patient and Physician Preferences for Attributes Associated with Biologic Treatments for Hidradenitis Suppurativa  
*John Ingram*
- T6-O-16** Brodalumab drug survival in patients with HS – a single-centre's experience  
*Emily Pender*
- T6-O-17** LAight therapy is an effective and gentle treatment for hidradenitis suppurativa in adolescence– Results from 96 patients.  
*Simone Garcovich*
- T6-O-18** Exploratory Trial of Topical Ruxolitinib for Early Stage Hidradenitis Suppurativa  
*Joslyn Kirby*
- T6-O-19** The inflammatory pattern of Hidradenitis suppurativa patients after treatment with antibiotics  
*Anke Koenig*
- T6-O-20** Insight into the window of opportunity: Low therapeutic burden is associated with better effectiveness of secukinumab in patients with moderate-to-severe hidradenitis suppurativa  
*Sofia Haselgruber*

**Poster Walk 1 – Group 4**

- T6-P-01** A Case of Palmoplantar Pustulosis-Like Paradoxical Reaction in a Patient with Hidradenitis Suppurativa Treated with Adalimumab.  
*Koremasa Hayama*
- T6-P-02** Successful treatment of ulceration in hidradenitis suppurativa with topical bucladesine: A case report  
*Ichiro Kurokawa*
- T6-P-03** "Bimekizumab in Hidradenitis Suppurativa: Real-world Insights from a 12-Month Study at a Tertiary Hospital in Northern Greece"  
*Athina- Ioanna Daponte*
- T6-P-04** Use of plasma with high titer neutralizing autoantibodies to type I interferons in patients with severe refractory flare-up of Hidradenitis Suppurativa as novel passive immunotherapy approach.  
*François Aubin*
- T6-P-05** Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in Hidradenitis Suppurativa  
*Johanna van Huijstee*
- T6-P-06** Efficacy and safety of infliximab in patients with moderate-severe hidradenitis suppurativa: a multicenter retrospective study.  
*Juan Segura Palacios*
- T6-P-07** Real-world effectiveness and safety of a combination of intense pulsed light and radiofrequency therapy for Hidradenitis Suppurativa  
*Georgios Nikolakis*

- T6-P-08** Adalimumab Drug Survival and Predictors of Discontinuation in Hidradenitis Suppurativa  
*Alexa Kimball*

**Poster Walk 2 – Group 3**

- T6-P-09** Clinical Outcomes of Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Real-world Response Rates  
*Federica Repetto*
- T6-P-10** Management of Hidradenitis Suppurativa in Tunisia: An Expert Consensus Using the Conventional Delphi Method  
*Mariam Fazzeni*
- T6-P-11** Cutaneous lupus erythematosus exacerbated by adalimumab in a patient with hidradenitis suppurativa: a case report and favorable response to secukinumab  
*Laura Pericet-Fernández*
- T6-P-12** Antimicrobial Stewardship in Hidradenitis Suppurativa  
*Francesca Prignano*
- T6-P-13** Long-term secukinumab effectiveness and safety in patients with moderate to severe hidradenitis suppurativa: a single center experience  
*Elia Rosi*
- T6-P-14** An Early Evaluation of Secukinumab Therapy in Adalimumab-Resistant Hidradenitis Suppurativa: A Prospective Case Series  
*Kiran Kaur Gurdial Singh*

**Poster Walk 3 – Group 1**

- T6-P-15** Clinical Experience of Adalimumab Biosimilar Hyrimoz in Moderate to Severe Hidradenitis Suppurativa. Switching from Adalimumab Originator Humira to Hyrimoz.  
*Anna Vatalachou*
- T6-P-16** Addition of Adalimumab to Surgery for Moderate to Severe Hidradenitis Suppurativa: A Friendly Summary of the Body of Evidence (FRISBEE)  
*Victor Meza Viteri*
- T6-P-17** Targeting NLRP3 with Molecular Dynamics: Pioneering a Novel Approach for Tailored Treatment in Hidradenitis Suppurativa  
*Sergio Crovella*
- T6-P-18** Should treatment with adalimumab in HS-patients with inactivity of the disease be discontinued?  
*Blanca Díaz-Ley*
- T6-P-19** Gaining feedback on a proposed clinical trial from people with hidradenitis suppurativa to improve the study experience and enhance recruitment  
*Latoya Palmer*
- T6-P-20** Phage therapy: a challenging opportunity for HS  
*Lene Bens*

- T6-P-21** PHARMACEUTICAL CARE IN PATIENTS WITH HIDRADENITIS SUPPURATIVA  
*Isabel Reina*
- T6-P-22** Therapeutic project of 210 HS patients from the official registry of “Andreas Sygros” Hospital for Venereal and Cutaneous Diseases  
*Aikaterini Liakou*
- T6-P-23** Virtual Patient Simulation improved clinical decision-making in the management of patients with hidradenitis suppurativa.  
*Elaine Bell*
- Poster Walk 4 – Group 3**
- T6-P-24** Treatment of pediatric hidradenitis suppurativa with bimekizumab: a case report  
*Giammarco Granieri*
- T6-P-25** Off-label Botox Treatment as an Add-on for Patients with Hidradenitis Suppurativa: A Retrospective Study  
*Ditte Saunte*
- T6-P-26** Upadacitinib in the treatment of concomitant hidradenitis suppurativa and atopic dermatitis: a case report  
*Giammarco Granieri*
- T6-P-27** Intravenous ertapenem - a novel treatment for the management of recurrent hidradenitis suppurativa flares  
*Emma Laverty*
- Poster Walk 5 – Group 2**
- T6-P-28** Dupilumab effectiveness in a case of prurigo nodularis and severe recalcitrant hidradenitis suppurativa.  
*Raffaele Dante Caposiena Caro*
- T6-P-29** Effectiveness and safety of bimekizumab in the treatment of patients with moderate-to-severe hidradenitis suppurativa: from clinical trial to reality  
*Alejandro Molina-Leyva*
- T6-P-30** Hidradenitis suppurativa, patients raise their voices: is pain management enough?  
*Claire Poreaux*
- T6-P-31** Unravelling Insights into the Mechanism of Action of Secukinumab in Ameliorating the Inflammatory Phenotype of Hidradenitis Suppurativa: Lessons from Diseased Skin Organ Culture  
*Marta Bertolini*
- T6-P-32** Severe forms of hidradenitis suppurativa on secukinumab treatment, efficacy and safety profile - real world experience.  
*Karolína Vorčáková*
- Poster Walk 6 – Group 1**
- T6-P-33** Neuropathic Symptoms in Hidradenitis Suppurativa: medical or surgical approach?  
*Antonio Martorell*

- T6-P-34** Demodex Mites in Patients with Follicular Phenotype Hidradenitis Suppurativa: A Possible Association  
*Rositsa Lavcheva*
- T6-P-35** Changes in thyroid hormone needs induced by cotrimoxazole given for hidradenitis suppurativa in a patient with concomitant hypothyroidism – A case report  
*Philippe Guillem*
- T6-P-36** Clinical and microbiome effects of bacteriophage therapy for HS  
*Cong Wang*

## **T7 Surgical Treatments**

- T7-O-01** Optimizing outcomes in hidradenitis suppurativa surgical treatment: a comprehensive analysis of postoperative complications and quality of life impact  
*Alessandra Michelucci*
- T7-O-02** Clinical Precision in Hidradenitis Suppurativa Lesion Excision: A Prospective Study of 110 Cases Utilizing Ultrasound-Guided Surgical Techniques  
*Antonio Martorell*
- T7-O-03** Deroofing in Hidradenitis Suppurativa: one-year experience in two Chilean health centers.  
*Francisco Reyes-Baraona*
- T7-O-04** Secukinumab treatment interruptions and post-operative safety profile in patients with moderate to severe hidradenitis suppurativa undergoing surgery: a post-hoc analysis from the SUNSHINE and SUNRISE trials  
*Falk Bechara*

### **Poster Walk 3 – Group 2**

- T7-P-01** Recurrence rates following excision of hidradenitis suppurativa: Prospective analysis of 74 patients  
*Anne-Cécile Ezanno*
- T7-P-02** Patient Satisfaction and Quality of Life Following Surgery for Hidradenitis Suppurativa  
*Benjamin Tobalem*
- T7-P-03** A novel method using tranexamic acid to manage intra-operative bleeding and post-inflammatory hyperpigmentation following deroofing surgery for hidradenitis suppurativa  
*Lauren Lam*
- T7-P-04** Deroofing technique with LASER CO2 for the treatment of HS lesions: Data from 7 HS patients from a single center study in Greece.  
*Aikaterini Liakou*
- T7-P-05** Wide surgical excision with 'star-like' wound closure for hidradenitis suppurativa: a 10-year experience in a Chilean center  
*Victor Meza Viteri*

- T7-P-06** Multidisciplinary consultation Dermatology + General Surgery in hidradenitis suppurativa: towards comprehensive and optimised care  
*Alejandro Molina-Leyva*
- T7-P-07** Immuno-surgery: the combination of STEEP surgical technique and biological therapy in the treatment of hidradenitis suppurativa  
*András Bánvölgyi*
- T7-P-08** Partial Closure as an Alternative to Secondary Intention Closure in Extensive Axillary Defects: A Case Series  
*Antonia Mori Sanchez*
- T7-P-09** Medical Tourism in Hidradenitis Suppurativa: An Irish Institution's experience  
*Elizabeth Keeling*

## **T8 Nursing and Supportive Care**

### **Poster Walk 6 – Group 2**

- T8-P-01** Nursing management of hidradenitis suppurativa in France: result of a practice survey  
*Samantha Gaspard*
- T8-P-02** Postoperative wound management in a patient with hidradenitis suppurativa, psoriasis and psoriatic arthritis on secukinumab therapy - case report  
*Ivana Mijalic*

## **T9 Other**

- T9-O-01** New perspectives on Mammary Hidradenitis Suppurativa  
*Ariany Denofre*
- Poster Walk 3 – Group 3**
- T9-P-02** HS patient demographics and clinical data from Lithuania  
*Tadas Raudonis*
- T9-P-03** Comparing Physician and Artificial Intelligence Chatbot Responses to Common Patient Questions Regarding Hidradenitis Suppurativa – a single-blind study  
*Miłosz Lewandowski*
- T9-P-04** Hidradenitis suppurativa: needs for future physicians caring for individuals with the disease  
*Aikaterini Tsentemeidou*
- T9-P-05** Human Placental Mesenchymal Stromal Cells Modulate Inflammation in Skin Co-culture Model of Hidradenitis Suppurativa: A Case Series Report  
*Vaiva Jariene*
- T9-P-06** Who are the hidradenitis suppurativa patients aged 50 and over?  
*Lila Desmarest*

**T9-P-07** Significant spontaneous daily fluctuation of inflammatory nodules and abscesses but not of draining tunnels in hidradenitis suppurativa / acne inversa

*Christos Zouboulis*

**T9-P-08** Coexistence of paradoxical psoriasis and erythema multiforme-like drug eruption in a patient with hidradenitis suppurativa on adalimumab therapy.

*Erkan Alpsoy*

**Poster Walk 5 – Group 3**

**T9-P-09** Hashtag HS Warrior on TikTok: harnessing an emerging social media platform to convey important health messages to teens.

*Laoise Griffin*

**T9-P-10** Squamous cell carcinoma occurring in hidradenitis suppurativa, a retrospective french study of 25 cases

*Sébastien Buche*

**T9-P-11** Artificial Intelligence and Hidradenitis Suppurativa: Validity and reliability of Artificial Intelligence by experts as public sources of information for patients

*Anne-Cécile Ezanno*

**T9-P-12** Important parameters of hidradenitis suppurativa severity - an opinion from clinical practice

*Aikaterini Tsentemeidou*

**T9-P-13** Mechanical Stress in Hidradenitis Suppurativa

*Elisabeth Haugsten*

**T9-P-14** Social dermatology


*Elisabeth Christensen*



This image shows a single page from a notebook or ledger. It features ten evenly spaced horizontal grey lines across its entire width. The top edge of the page has a faint vertical margin line on the left side, creating a narrow left margin. The rest of the page is open space between the horizontal lines, suitable for writing. There are no markings, text, or illustrations on the page.

[illegible]

[illegible]



# INDUSTRY PROGRAM AND EXHIBITION



# INDUSTRY SYMPOSIA

## Thursday, February 08, 2024

**12:45-13:45****Industry Lunch Symposium – Abbvie****Auditorium  
Lumière**

Looking towards a bright future in Hidradenitis Suppurativ

*Hessel van der Zee**Antônio Martorell**Mariano Suppa***14:00-15:00****Industry Lunch Symposium – UCB****Auditorium  
Lumière**

Unlocking the future of HS care

*Philippe Guillem**Hessel van der Zee**Brian Kirby*

## Friday, February 09, 2024

**12:45-13:45****Industry Lunch Symposium – Novartis****Auditorium  
Lumière**Hidradenitis suppurativa: a multilayered disease requiring a  
multilayered approach*Ziad Reguiaï**John Frew**Jacek Szepietowski*

# Looking towards a bright future in Hidradenitis Suppurativa

Thursday, 8 February 2024  
12:45–13:45 CET

## IN THIS SESSION, WE WILL:

- Discuss emerging therapies targeting key drivers in HS pathogenesis
- Provide insights on HS management and aspirations regarding treatment goals
- Explore raising the standard of care in HS through precision medicine

### Chair:



**Assoc. Prof. Hessel van der Zee**  
Erasmus MC,  
Rotterdam, The Netherlands



**Assoc. Prof. Antonio Martorell**  
Hospital of Manises,  
Valencia, Spain



**Assoc. Prof. Mariano Suppa**  
Université Libre de Bruxelles,  
Brussels, Belgium



This symposium is open to health care providers only.  
This symposium is organized and funded by AbbVie.  
ABBV-AA-03217-E | V1 | Approved December 2023

# SPONSORS

We would like to thank all our sponsors for their support and are looking forward to further collaboration!

## Platinum Sponsors

### ABBVIE

[www.abbvie.com](http://www.abbvie.com)

The AbbVie logo, featuring the word "abbvie" in a lowercase, rounded, sans-serif font.

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions, such as hidradenitis suppurativa.

### NOVARTIS

[www.novartis.com](http://www.novartis.com)

The Novartis logo, consisting of a stylized orange and blue flame-like symbol followed by the word "NOVARTIS" in a blue, serif, all-caps font.

Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About 108,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world. Find out more at <https://www.novartis.com>

### UCB

[www.ucb.com/disease-areas/hidradenitis-suppurativa](http://www.ucb.com/disease-areas/hidradenitis-suppurativa)

The UCB logo, featuring a blue square with a white stylized 'u' and 'c' inside, followed by the text "Inspired by patients. Driven by science." in a blue, sans-serif font.

UCB is a global biopharmaceutical company dedicated to discovering and developing innovative medicines that transform patients' lives. We are committed to putting patients at the centre of our world, with a focus in immunology including hidradenitis suppurativa.

UCB is working to advance science and embrace new knowledge. We leverage scientific advances in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs and practical solutions.

Intended for Healthcare Professionals only

# UNLOCKING THE FUTURE OF HS CARE

THURSDAY, 8<sup>TH</sup> FEBRUARY, 2024

13:45–14:45 CET, Lyon Convention Centre, Lyon, France

## EHSF 2024

At this educational symposium you will learn to:

Recognise the impact of delayed versus timely diagnosis on patients with HS

Discuss the role of inflammatory mediators in the pathobiology of HS and how these have driven recent advances in the development of new treatment options

Associate how earlier use of biologics in the treatment paradigm and the use of surgery can help improve long-term outcomes

### Welcome and introduction

#### Exploring the patient journey:

Where are we today?

#### Understanding the drivers of HS:

Learnings from the science

#### Managing HS with biologics:

Looking to the future

#### How can we improve care for our patients with HS?

Audience Q&A

#### Meening close



UCB Patient Ambassador



**Dr Philippe Guillem (Chair)**  
Clinique du Val d'Ouest,  
Lyon,  
France



**Prof Brian Kirby**  
University College Dublin  
& St Vincent's University  
Hospital,  
Dublin, Ireland



**Prof Hessel van der Zee**  
Erasmus MC and  
DermaHaven,  
Rotterdam Netherlands



Inspired by **patients**.  
Driven by **science**.

HS, hidradenitis suppurativa EHSF, European Hidradenitis Suppurativa Foundation  
This symposium is organised and funded by UCB  
© UCB Biopharma SRL, 2024. All rights reserved.  
Date of preparation: January 2024 EU-BK-2300198

## Silver Sponsors

**BOEHRINGER INGELHEIM****[www.boehringer-ingelheim.com/de/](http://www.boehringer-ingelheim.com/de/)**

Family owned since it was established in 1885, Boehringer Ingelheim is one of the world's top 20 pharmaceutical companies. Our 50.000 employees bring value through innovation across 3 business areas: human health, animal health, and biopharmaceuticals.

Inflammatory diseases can greatly impact patients' lives physically and emotionally. With a deep understanding of molecular pathways, we are pioneering scientific breakthroughs that target, repair, and prevent inflammatory disorders.

**Boehringer  
Ingelheim****INCYTE****[www.incyte.com](http://www.incyte.com)**

Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders. The Company is advancing a diversified portfolio of clinical candidates across Oncology and Inflammation & Autoimmunity.





# When you care, your work is never done

UCB has a proven heritage in immunology.  
We harness evidence-based, trailblazing science to  
deliver life-changing treatments and personalized services that  
address persistent unmet needs across the healthcare ecosystem.



Inspired by **patients.**  
Driven by **science.**

# HS

hides  
in the  
shadows

*This is a representative patient image.*

## TOGETHER, WE CAN CHANGE THAT

Often underrecognized and undiagnosed, the chronic and progressive inflammation of HS may wreak havoc on patients' lives by causing debilitating pain, irreversible scarring, and emotional burden.<sup>1-6</sup> Don't wait for HS to progress.



Visit our Novartis booth to learn more

 NOVARTIS

HS=hidradenitis suppurativa.


**References:** 1. Daxhelet M et al. *Dermatology*. 2020;236(5):431-438. 2. Kokolakis G et al. *Dermatology*. 2020;236(5):421-430. 3. Kirby JS. *J Am Acad Dermatol*. 2016;74(6):1269-1270. 4. Matusiak L et al. *Acta Derm Venereol*. 2010;90(3):264-268. 5. Garg A et al. *J Am Acad Dermatol*. 2020;82(2):366-376. 6. van der Zee HH et al. *Br J Dermatol*. 2022;186(2):355-356.

December 2023  
387865

© 2023 Novartis Pharma AG

# INDUSTRY BOOTH PLAN

Industrial Exhibition: Forum 2 & 3



## LIST OF BOOTHS:

1. Abbvie
2. UCB
3. Novartis
4. Boehringer Ingelheim
5. Incyte

## OPENNING HOURS

**Wednesday, February 7, 2024**

08:00-18:30

**Thursday, February 8, 2024**

08:00-18:00

**Friday, February 9, 2024**

08:00-18:00



# IMPRINT

## **Scientific Organizer**

European Hidradenitis Suppurativa  
Foundation e.V.  
Auenweg 38, 06847 Dessau-Rosslau  
[www.ehsf.eu](http://www.ehsf.eu)

Prof. Dr. Christos C. Zouboulis  
President of the EHSF e.V.

## **Legal Organizer & PCO**

MCI Deutschland GmbH  
Markgrafenstrasse 56  
10117 Berlin  
T: +49 30 20459230  
F: +49 30 2045950

## **Congress venue**

Centre de Congrès de Lyon  
50, quai Charles de Gaulle  
69463 LYON Cedex 06  
France

## **Contact**

Project Management  
Anahit Balayan, Daniela Angeloni  
T: +49 30 204 59 337  
[ehsf@wearemci.com](mailto:ehsf@wearemci.com)

Sponsoring/Exhibition  
Kristina Van Cleave  
T: +49 30 20459469  
[ehsf-sponsoring@wearemci.com](mailto:ehsf-sponsoring@wearemci.com)

Printing date: 22.01.2024

